FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures Pittsburgh Post Gazette In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for BPC 157: Prohibited peptide and unapproved drug in supplements The Human Lab Rats Injecting Themselves with Peptides Office for Science and Society McGill University Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law